S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
BREAKING: The truth about war with China (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News

$38.04
-0.14 (-0.37%)
(As of 06/2/2023 ET)
Compare
Today's Range
$37.93
$38.83
50-Day Range
$23.00
$38.12
52-Week Range
$22.89
$40.15
Volume
42,315 shs
Average Volume
20,186 shs
Market Capitalization
$1.43 billion
P/E Ratio
56.78
Dividend Yield
N/A
Price Target
$35.00

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
8.0% Downside
$35.00 Price Target
Short Interest
Healthy
0.86% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Taro Pharmaceutical Industries in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

872nd out of 983 stocks

Pharmaceutical Preparations Industry

438th out of 486 stocks


TARO stock logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Taro Provides Results for Year Ended March 31, 2023
Urticaria Drug Market Business Report [2023-2030]
Oxcarbazepine Market Market Trends By 2030
See More Headlines

TARO Price History

TARO Company Calendar

Last Earnings
10/28/2021
Today
6/03/2023
Next Earnings (Estimated)
7/26/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
1,455
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
-8.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$25.44 million
Pretax Margin
6.67%

Debt

Sales & Book Value

Annual Sales
$572.95 million
Cash Flow
$1.80 per share
Book Value
$46.05 per share

Miscellaneous

Free Float
32,398,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
0.60

Key Executives

  • Uday Vijaykumar Baldota
    Chief Executive Officer & Director
  • William J. Coote
    Chief Financial, VP & Accounting Officer
  • Hagai Reingold
    Vice President & Head-Operations
  • Itamar Karsenti
    Vice President & Head-Operations
  • Avi Avramoff
    Vice President & Head-Research & Development













TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings
or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month price targets for Taro Pharmaceutical Industries' shares. Their TARO share price forecasts range from $35.00 to $35.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts price targets for TARO
or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2023?

Taro Pharmaceutical Industries' stock was trading at $29.04 at the start of the year. Since then, TARO shares have increased by 31.0% and is now trading at $38.04.
View the best growth stocks for 2023 here
.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a increase in short interest in May. As of May 15th, there was short interest totaling 69,200 shares, an increase of 24.2% from the April 30th total of 55,700 shares. Based on an average trading volume of 20,300 shares, the days-to-cover ratio is presently 3.4 days. Currently, 0.9% of the company's stock are sold short.
View Taro Pharmaceutical Industries' Short Interest
.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our TARO earnings forecast
.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced its quarterly earnings data on Thursday, October, 28th. The company reported $0.66 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.02 by $0.36. The business earned $131.99 million during the quarter, compared to analysts' expectations of $153.23 million. Taro Pharmaceutical Industries had a trailing twelve-month return on equity of 1.48% and a net margin of 4.44%. During the same period last year, the company earned $1.18 EPS.

What ETFs hold Taro Pharmaceutical Industries' stock?

ETFs with the largest weight of Taro Pharmaceutical Industries (NYSE:TARO) stock in their portfolio include ARK Israel Innovative Technology ETF (IZRL) and iShares MSCI Israel ETF (EIS).VanEck Israel ETF (ISRA).

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of retail and institutional investors. Top institutional investors include Krensavage Asset Management LLC (1.71%), Renaissance Technologies LLC (1.59%), Dimensional Fund Advisors LP (1.52%), Brandes Investment Partners LP (1.23%), Hotchkis & Wiley Capital Management LLC (0.76%) and Acadian Asset Management LLC (0.69%).

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $38.04.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.43 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.67 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

The company employs 1,455 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -